Podcasts about nephrectomy

RECORDED VIA ZOOMEmmilia O'Sullivan's book is called I Should Be F'N Dead!After recording and producing her audiobook I can assure you that this brave young lady is here for a reason.She has experienced among others, the following health challenges:A kidney removed, nephrectomy, osteoporosis, spinal fusion, cardiac arrest, pulmonary embolism, kidney failure, sepsis, a kidney transplant, non-Hodgkin's lymphoma, pneumonia, and a craniotomy.Not only did she have to face all of these, incredibly she overcame each one. Does she have a superpower and how the heck did she deal with everything over an intense 10-year period between her young age of 20 - 30 years old. We discuss this and a whole lot more chatting on The Simone Feiler Podcast where Emmilia shares insights of what she went through and what she believes has helped her overcome everything to now being a published author and a soon to be podcaster and life coach.If you're dealing with any health issues, in fact, any hardships whatsoever, this is a must listen chat and I highly recommend you listen to her outstanding audiobook, self-narrated by Emmillia herself called I Should Be F'N Dead! - Staying Positive Through a Sh1t Load of Heath Challenges.Find out more and connect with Emmilia O'Sullivan at the following links:Emmilia's WebsiteInstagramFacebookLinkedInTikTokPlease LIKE and SUBSCRIBE to my channel to hear more conversations with amazing Aussie authors like Emmilia - Thank you :)What's your story?I'd love to chat!Contact me here.

Send us a Text Message.Curious about the real challenges of performing a unilateral nephrectomy in dogs? Join us for an enlightening conversation with Dr. Laura Selmic and Carley Johnson. Carly delves into the findings from a recent JAVMA article, revealing the high rate of complications during and after this surgical procedure. From renal neoplasia to end-stage hydronephrosis and severe renal infections, discover the complex conditions that often necessitate nephrectomy and the intricate balance veterinarians must maintain to ensure a successful outcome.Gain insights into the most common intraoperative and postoperative hurdles, such as low blood pressure, hemorrhage, and acute kidney injuries. Learn how, despite these risks, most dogs ultimately recover well. Laura discusses the pressing need for long-term data to better guide veterinary professionals and pet owners. Don't miss this chance to elevate your understanding of this surgical procedure.JAVMA article: https://doi.org/10.2460/javma.24.01.0005INTERESTED IN SUBMITTING YOUR MANUSCRIPT TO JAVMA ® OR AJVR ® ? JAVMA ® : https://avma.org/JAVMAAuthors AJVR ® : https://avma.org/AJVRAuthorsFOLLOW US:JAVMA ® : Facebook: Journal of the American Veterinary Medical Association - JAVMA | Facebook Instagram: JAVMA (@avma_javma) • Instagram photos and videos Twitter: JAVMA (@AVMAJAVMA) / Twitter AJVR ® : Facebook: American Journal of Veterinary Research - AJVR | Facebook Instagram: AJVR (@ajvroa) • Instagram photos and videos Twitter: AJVR (@AJVROA) / Twitter JAVMA ® and AJVR ® LinkedIn: https://linkedin.com/company/avma-journals

For Urologists, there are not that many papers that come along where we can say - "this will almost immediately change my practice". But KEYNOTE-564 looks like one of those! A large phase III randomised trial of adjuvant pembro following nephrectomy for renal cell carcinoma in patients deemed at higher risk for recurrence. Regular listeners/viewers might remember we discussed this on GU Cast back in August 2021 when the disease-free survival endpoint was published in NEJM, and it would be fair to say we were cautious and kept saying "we need to wait for the overall survival data". Well here we are! Patients who received pembro for one year had a 38% reduced risk of death. Big news! We are joined again by Dr Alex Kutikov, Urologist at Fox Chase Cancer Centre, who joined us on the original podcast. We are also joined by his colleague GU Medical Oncologist, Dr Matt Zibelman, who has a lot of experience in this area having been an investigator on the IMmotion 010 study. Unfortunately lead author Dr Toni Choueiri could not join us this time but he gets plenty of mentions!This is a Themed Podcast supported by our Silver Partners, MSD, manufacturers of pembrolizomab, through an educational grant. MSD had no input into the content of this podcast. Even better on our YouTube channelLinks:Full NEJM paper Previous GU Cast on K-564

In 'Episode 1' of a series on "Metastatic renal cell carcinoma", Assist. Prof. Andrea Mari (IT) and Prof. Ketan Badani (US) discuss "The role of cytoreductive nephrectomy for metastatic renal cell carcinoma ".Assist. Prof. Andrea Mari and Prof. Ketan Badani delve into the pivotal role of cytoreductive nephrectomy in the management of metastatic renal cell carcinoma (mRCC). They talk about the rationale behind this surgical intervention, its impact on patient outcomes, and the evolving landscape of treatment strategies in advanced kidney cancer.Whether you're a healthcare professional or someone seeking insights into cutting-edge cancer therapies, this discussion promises to illuminate the complexities of renal cell carcinoma management.

Monday morning live with Natasa Denman featuring one of her amazing authors, Emmilia Sullivan. Emmilia O'Sullivan is an inspirational young lady who has faced life's challenges head on and always does so with positivity and humour. She is full of life, enthusiastic, and very passionate about providing support to people like her that have been through horrendous medical issues/diagnoses. In Emmilia's short 30 years, she has endured more medical diagnoses' than one person would experience in their entire lifetime including Nephrectomy, Kidney Transplant, Spinal Fusion, Neck Dissections, Cardiac Arrest, Craniotomy, Non-Hodgkin's Lymphoma, Pneumonia, Sepsis and so much more! She has defied all odds over and over again and is here to tell the tale. Emmilia has written a book about her life in the hope to inspire others and show them you can come out great on the other end so that is exactly what she did and now shares her experiences with “I Should be F'N Dead!” An open and approachable speaker, Emmilia shares all her experiences within the medical world with her audiences leaving them hopeful of the future and inspired to overcome any challenge they may face. Having someone that you can relate to gives a sense of comfort during the bad times and knowing that you are not alone truly helps. And as an added bonus, she may even make you laugh! Emmilia is available to speak to support groups, events, organisations, schools and within the community. Her main topics are: The Power of a Positive Mindset - How to cope when receiving a life changing medical diagnoses - Never giving up – The John Cena Way - Celebrating the small wins The Ultimate Recovery Conditions - The keys to looking after yourself - How to listen to your body - Building the resilience muscle Getting Up From Rock Bottom - The power of practicing gratitude - Finding your purpose - Baby Steps for Big Outcomes To enquire about engaging Emmilia to speak at your next event email abc.com.au to enquire about pricing and availability. You can buy Emmilia's book here: https://www.paypal.com/instantcommerce/checkout/B2US97798F6N2 Find us at http://www.writeabook.com.au Join our Facebook Community: Author Your Way to Riches: https://www.facebook.com/groups/authoryourwaytoriches Subscribe to my YouTube Channel: http://bit.ly/NatasaDenmanYouTube

February 24, 2023Mark, Ray, and Scott discuss questions that came into the PRS Community.   I listened to the most recent podcast episode regarding the updated PCNL codes and I'm still confused on why we can't bill 50436 or 50437 with 50080/50081? Dilation was deleted from the code description and I attended an AUA webinar in Dec 2022 that said the dilation could be reported separately. What's changed?Good morning, Does 50548 include laparoscopic bladder cuff, or would the bladder cuff be separately billable with 51999? Bladder cuff is not mentioned in the code descriptor.It was discussed at New Orleans seminar that retrograde pyelogram (74420) was not appropriate to report with stent exchanges/ureteroscopic procedures (as it is considered included as part of the guidance for these procedures). Is this direction based on CPT guidance or is there another reference?   Join The Urology Coding Compliance and Education Network and get started today!Pricing and More Information The Thriving Urology Practice Facebook Grouphttps://www.facebook.com/groups/ThrivingPractice  Join the discussion:Urology Coding and Reimbursement Group - Join for free and ask your questions, and share your wisdom.Click Here to Start Your Free Trial of AUACodingToday.com 

After an unexpected opportunity arises, Lexman takes on a Nephrectomy by Highjacker in a daring bid to win the rights to the CARPUS gene. What unfolds is an unlikely but entertaining story that is sure to leave you asking what would happen if the laws of the universe were changed just a bit...

Drs Sumanta Pal and Tian Zhang review the state of the data on adjuvant treatment with immunotherapy for patients with renal cell carcinoma, including where current clinical trials stand. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/968737). The topics and discussions are planned, produced, and reviewed independently of advertiser. This podcast is intended only for US healthcare professionals. Resources Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study https://clinicaltrials.gov/ct2/show/NCT03793166 The Role of Targeted Therapy in the Management of High-Risk Resected Kidney Cancer: What Have We Learned and How Will It Inform Future Adjuvant Trials https://journals.lww.com/journalppo/Abstract/2020/09000/The_Role_of_Targeted_Therapy_in_the_Management_of.3.aspx Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy https://www.nejm.org/doi/10.1056/NEJMoa1611406 Sutent (sunitinib) prescribing information https://labeling.pfizer.com/showlabeling.aspx?id=607 Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma (KEYNOTE-564) https://www.nejm.org/doi/full/10.1056/NEJMoa2106391 RAMPART: A Phase III Multi-arm Multi-stage Trial of Adjuvant Checkpoint Inhibitors in Patients With Resected Primary Renal Cell Carcinoma (RCC) at High or Intermediate Risk of Relapse https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8520913/ A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy (IMmotion010) https://clinicaltrials.gov/ct2/show/NCT03024996 A Comparison of Sunitinib with Cabozantinib, Crizotinib, and Savolitinib for Treatment of Advanced Papillary Renal Cell Carcinoma: a Randomised, Open-Label, Phase 2 Trial https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8687736/ A Study Comparing Nivolumab, Nivolumab in Combination With Ipilimumab and Placebo in Participants With Localized Kidney Cancer Who Underwent Surgery to Remove Part of a Kidney (CheckMate 914) https://clinicaltrials.gov/ct2/show/NCT03138512 PROSPER: Phase III RandOmized Study Comparing PERioperative nivolumab versus observation in patients with renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN EA8143). https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.TPS4596 Pembrolizumab as Post Nephrectomy Adjuvant Therapy for Patients With Renal Cell Carcinoma: Results From 30-Month Follow-up of KEYNOTE-564 https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.6_suppl.290 Leibovich RCC Model: Prediction of Progression After Radical Nephrectomy for patients With Clear Cell Renal Cell Carcinoma https://cancernomograms.com/nomograms/972 Effects of Adjuvant Sorafenib and Sunitinib on Cardiac Function in Renal Cell Carcinoma Patients without Overt Metastases: Results From ASSURE, ECOG 2805 https://aacrjournals.org/clincancerres/article/21/18/4048/117759/Effects-of-Adjuvant-Sorafenib-and-Sunitinib-on

Episode 105: Renal Cell Carcinoma. Manpreet and Jon-Ade explain how to diagnose renal cell carcinoma. Introduction about age and kidney transplant by Dr. Arreaza and Dr. Yomi. Introduction: Too old for a new kidney?By Hector Arreaza, MD. Discussed with  Timiiye Yomi, MD.Today we will be talking about the kidneys, those precious bean-shaped organs that detoxify your blood 24/7. Amazingly, we can live normal lives with one kidney, but when the kidney function is not good enough to meet the body's demands, patients need to start kidney replacement therapy. Modern medicine has made a lot of advances with dialysis, but the perfection of a kidney has not been outperformed by any machine yet. That's why kidney transplant is the hope for many of our patients with end-stage kidney disease.The need for a kidney transplant is growing, likely due to increasing chronic diseases such as diabetes and hypertension, and also because of an increase in elderly population. About 22% of patients on the kidney transplant waiting list are over age 65. A cut-off age to receive kidney transplant has not been established across the globe. Different countries use different criteria for the maximum age for transplant. The American Society of Transplantation's guidelines states “There should be no absolute upper age limit for excluding patients whose overall health and life situation suggest that transplantation will be beneficial.” So, if your patient is older than 65 and needs a kidney, they may qualify for a transplant, and age should not be an absolute contraindication to receive it. Actually, older patients may have lower risk of rejection due to a theoretically weaker immune system. A live donor is likely to be a better option for elderly patients. A condition that would make your elderly patient a poor candidate for kidney transplant would be frailty. Common contraindications to kidney transplant include active infections or malignancy, uncontrolled mental illness, ongoing addiction to substances, reversible kidney failure, and documented active and ongoing treatment nonadherence.So, remember to take these factors into consideration when deciding if you need to refer your elderly patients for a kidney transplant, there is no such thing as being too old for a new kidney if your patient meets all the criteria for a transplant.This is Rio Bravo qWeek Podcast, your weekly dose of knowledge brought to you by the Rio Bravo Family Medicine Residency Program from Bakersfield, California. Our program is affiliated with UCLA, and it's sponsored by Clinica Sierra Vista, Let Us Be Your Healthcare Home. This podcast was created for educational purposes only. Visit your primary care physician for additional medical advice. Renal Cell Carcinoma. By Manpreet Singh, MS3, Ross University School of Medicine, and Jon-Ade Holter, MS3 Ross University School of Medicine. Moderated by Hector Arreaza, MD. Definition:Renal cell carcinoma is a primary neoplasm arising form the renal cortex. 80-85 percent of renal tumors are renal cell carcinomas followed closely by transitional cell renal cancer and Wilms tumor.  Epidemiology: In 2022, 79,000 new cases of kidney cancer were diagnosed with almost 14,000 mortalities. There is a 2:1 male to female ratio and the average age is 64 and normally 65-74. African Americans and American Indians have a higher prevalence rate compared to other racial groups. The lifetime risk for developing kidney cancer in men is about 1 in 46 (2.02%) and 1 in 80 (1.03%) in women.  Risk Factors associated with RCC: Anything that causes assault to the kidneys and affects its function would cause increased demand, injury, and inflammation. This assault can lead to cell derangement and lead to cancer. The risk factors that have been associated with RCC are smoking, obesity, HTN, family history of kidney cancer, Trichloroethylene (a metal degreaser used in large manufacturing factories), acetaminophen, and patients with advanced kidney disease needing dialysis. Patients with syndromes that cause multiple types of tumors: VHL (von Hippel-Lindau) deficiency, a tumor suppressor, gives rise to clear cell renal cell carcinoma. Familial inheritance of VHL deficiency is mostly found in patients that have RCC at a very young age, before 40 y/o. Other tumors can be found in the eye, brain, spinal cord, pancreas, and pheochromocytomas.Hereditary leiomyoma-renal cell carcinoma due to FH gene mutations causing women who have leiomyomas to have a higher risk of developing papillary RCC.Birt-Hogg-Dube (BHD) syndrome mutation in FLCN gene who develop various skin and renal tumors.Cowden syndrome is a mutation in the PTEN gene giving rise to cancers associated with breast, thyroid , and kidney cancers.Tuberous sclerosis causes benign tumors of the skin, brain, lungs, eyes, kidneys, and heart. Although kidney tumors are most often benign, occasionally they can be clear cell RCC. Screening For RCC:Screening is unnecessary because of the low prevalence of this cancer in the general population, though certain groups require annual repeat imaging via US, CT, or MRI. Inherited conditions that are associated with RCC such as VHL syndrome or Tuberous SclerosisESRD patients who have been on dialysis for 3-5 yearsFamily history of RCCPrior kidney irradiation Clinical Picture: Most patients with RCC are asymptomatic until cancer grows large enough to cause disruption of local organs, such as the kidney, bladder, or renal vein, and dysregulates other organs via metastasis. Therefore, it's important to look at other signs and symptoms caused by RCC.  The patient most likely will be an older male who presents with the classic triad of: Flank pain: caused by rapid expansion and stretching of the renal capsule.Hematuria: occurs from the invasion of the neoplasm into the collecting duct.Palpable abdominal mass: mass tends to be homogenous and mobile with respirations. Though this presents only in 9% of patients during the presentation, having physical symptoms is a sign of advanced disease and 25% of patients with these signs tend to have distant metastasis.  Anemia: normally associated with anemia of chronic disease. It precedes the disease by at least 8 months to 1 year. Males can develop varicoceles because of decreased emptying due to neoplasm obstruction. Patients normally develop varicoceles on the left due to the spermatic vein emptying in the higher resistance left renal vein, which causes backup of the blood in the pemphigus plexus. Though a right-sided varicocele should raise a higher suspicion of obstruction due to the spermatic vein draining directly into the IVC which is lower in resistance. A right-sided varicocele is seen in approximately 11 percent of patients. The paraneoplastic syndrome can also arise from RCCEpo: Erythrocytosis with symptoms of weakness, fatigue, headache, and joint pain.PTHrP: PTH-related peptide acts like PTH which gives rise to hypercalcemia with the prevalent symptoms of arthritis, osteolytic lesions, confusions, tetany, ventricular tachycardia, shortened QTc, and nausea and vomiting.Renin: overproduction from the juxtaglomerular cells can cause disarrangement of the RAAS system causing hypertension.Others also like ACTH and beta-HCG. Other disorders present include hepatic dysfunction, cachexia, secondary amyloidosis, and thrombocytosis. Workup If a patient comes in with painless hematuria, then the first test should be abdominal CT or abdominal ultrasound. A CT is more sensitive than the US but it can quickly indicate if the abdominal mass felt can be a cyst or a solid tumor.  US of kidneys should show if it's a simple cyst:-The cyst is round and sharply demarcated with smooth walls- It's anechoic – appears solid black-There is a strong posterior wall echo-Use the Bosniak classification to classify mass  Bosniak I: benign simple cyst with thin wall less than equal to 2mm, no septa or calcifications. No future workup is needed. Bosniak II: benign cyst, 3 cm diameter, requires f/u with US/CT/MRI at 6 months, 12 months, and annually for the next 5 years. Chance of malignancy: 5%.  Bosniak III: indeterminate cystic mass with thick, irregular or smooth walls. This requires nephrectomy or radiofrequency ablation. Chance of malignancy: 55%  Bosniak IV: Clearly a malignancy its grade III with enhancing soft tissue components that its independent from the wall or septum. Requires total or partial nephrectomy. Chance of malignancy 100%.  CT of the kidneys for a neoplasm should show:-Thickened irregular walls or septa -Enhancement after contrast injection are suggestive of malignancy-CT can also help detect invasion in local tissue areas such as renal vein and perinephric organs  MRI is used if the patient cannot use contrast or kidney function is poor. MRI can also evaluate the growth of the cancer. Other imaging studies:Other imaging studies that may be useful for assessing for distant metastases include bone scan, CT of the chest, magnetic resonance imaging (MRI), and positron emission tomography (PET)/CT. Treatment and staging Nephrectomy, partial or total, will be used as the initial tissue collection for pathology. If the patient is not a surgical candidate, you can also obtain a percutaneous biopsy. The nephrectomy is preferred because first, it serves as a definitive treatment option, but also it allows for definitive staging of the cancer with tumor and nodal staging. Regardless of the size, any solid mass may indicate malignancy and point towards RCC, requiring resection.   TNM staging Stage I: Tumor is 7cm across or smaller and only in the kidney with no lymph nodes or distant mets. T1N0M0 Stage IIa: Tumor size is larger than 7cm but still in the kidney but no invasion of lymph node or mets. T2N0M0 Stage IIb: Tumor is growing into the renal vein or IVC, but not into neighboring organs such as adrenals or Gerota's fascia and still lacks lymph node invasion and mets. T3N0M0.  Stage III: Tumor can be any size but has not invaded outside structures such as adrenals, though nearby lymph node invasion is present but not distant. There is no distant mets. T3N1M0. Stage IV:  The main tumor is beyond the Gerota's fascia and may grow into the adrenal gland . It may or may not spread to the lymph nodes or may not have distant mets. Stage IV also consists of any cancer that has any number of distant mets. T4 Adjuvant therapy can be done with immune therapy. Conclusion: Now we conclude our episode number 105 “Renal cell carcinoma.” This type of cancer may be asymptomatic until it is large enough to cause symptoms. Keep it on your list of differentials on patients with hematuria, flank pain, weight loss, and abnormal imaging. Keep in mind the features of simple kidney cysts vs complex cysts when assessing kidney ultrasounds. Your patient will be grateful for an early diagnosis of RCC and a prompt treatment. Even without trying, every night you go to bed being a little wiser.This week we thank Hector Arreaza, Timiiye Yomi, Manpreet Singh, Jon-Ade Holter. Thanks for listening to Rio Bravo qWeek Podcast. If you have any feedback, contact us by email at RioBravoqWeek@clinicasierravista.org, or visit our website riobravofmrp.org/qweek. Audio edition: Suraj Amrutia. See you next week!  Bibliography: Is There a Cut Off Age for Kidney Transplant?, Mayo Clinic Connect, Jul 18, 2017, https://connect.mayoclinic.org/blog/transplant/newsfeed-post/is-there-a-cut-off-age-for-kidney-transplant/ Atkins, Michael. “Clinical Manifestations, Evaluation, and Staging of Renal Cell Carcinoma.” UpToDate, January 21. https://www.uptodate.com/contents/clinical-manifestations-evaluation-and-staging-of-renal-cell-carcinoma American Cancer Society. “Key Statistics About Kidney Cancer”. Cancer.Org, 2022, https://www.cancer.org/cancer/kidney-cancer/about/key-statistics.html. Escudier B, Porta C, Schmidinger M, Rioux-Leclercq N, Bex A, Khoo V, Grünwald V, Gillessen S, Horwich A; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Ann Oncol. 2019 May 1;30(5):706-720. doi: 10.1093/annonc/mdz056. PMID: 30788497. https://pubmed.ncbi.nlm.nih.gov/30788497/. Gaillard, F., Bell, D. Bosniak classification system of renal cystic masses. Reference article, Radiopaedia.org. (accessed on 20 May 2022) https://doi.org/10.53347/rID-1006. Kopel J, Sharma P, Warriach I, Swarup S. Polycythemia with Renal Cell Carcinoma and Normal Erythropoietin Level. Case Rep Urol. 2019 Dec 11;2019:3792514. doi: 10.1155/2019/3792514. PMID: 31934488; PMCID: PMC6942735. https://pubmed.ncbi.nlm.nih.gov/31934488/. Leslie SW, Sajjad H, Siref LE. Varicocele. [Updated 2022 Feb 14]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK448113/. Maguire, Claire. “Understanding Endoscopic Ultrasound and Fine Needle Aspiration.” Educational Dimension, Educational Dimensions, 1 Jan. 2007, educationaldimensions.com/eLearn/aspirationandbiopsy/eusterm.php. Maller, V., Hagir, M. Renal cell carcinoma (TNM staging). Reference article, Radiopaedia.org. (accessed on 20 May 2022) https://doi.org/10.53347/rID-4699. Palapattu GS, Kristo B, Rajfer J. Paraneoplastic syndromes in urologic malignancy: the many faces of renal cell carcinoma. Rev Urol. 2002 Fall;4(4):163-70. PMID: 16985675; PMCID: PMC1475999. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1475999/.

Thank you for listening to another episode of DWP! For Phillip Fairbanks book. https://www.amazon.com/Pedogate-Primer-pedophilia-Philip-Fairbanks-ebook/dp/B08N3X5341 To support Nephrectomy https://nephrectomyslam.bandcamp.com/merch Mini Tour in Texas 6/24-6/26 San Antonio Corpus Christi Houston IG - @NephrectomyOfficial Jaymes IG @elchapogonzo EMF protective beanie

Thank you for listening to another episode of DWP! For Phillip Fairbanks book. https://www.amazon.com/Pedogate-Primer-pedophilia-Philip-Fairbanks-ebook/dp/B08N3X5341 To support Nephrectomy https://nephrectomyslam.bandcamp.com/merch Mini Tour in Texas 6/24-6/26 San Antonio Corpus Christi Houston IG - @NephrectomyOfficial Jaymes IG @elchapogonzo EMF protective beanie

Marissa Willis has survived kidney cancer and through the Kidney Cancer Association works as an advocate for others on a kidney cancer journey. Her proactive approach resulted in the cancer being caught at Stage II.

  Welcome to another episode of the Monday Night MasterDebaters, tonight we had Ryan from Dangerous World, Mat from The Great Deception, Tyson our brother from Canada, and Jaymes from the band Nephrectomy.  We had to talk about the Ottawa Freedom Convoy, the tyranny of Turd-eau, UN Troops on the ground, and Crushing of rights & civil liberties. True fascism, indoctrination in the Upside Down World and the dedication of the corporate media and counterparts to their narrative. We then switched gears to Ukraine, China Olympics, China potential Ebola spreader?, Fear of Death, Terrorism->Virus the use of invisible enemies, Transhumanism, Music and Music World in 2022, parenthood, and so much more.   Jaymes from Nephrectomy IG: @elchapogonzo @nephrectomyofficial https://www.facebook.com/Nephrectomy https://nephrectomyslam.bandcamp.com Tyson our Canadian Brother IG: @that_crazy_canuk Ryan from Dangerous World Podcast Patreon: https://www.patreon.com/DangerousWorldPodcast/posts IG: @dangerousworldpod Merch: https://dangerousworldstore.com/ Mat from The Great Deception Podcast https://altmediaunited.com/the-great-deception-podcast/ IG: @thegreatdeceptionpodcast YouTube: https://youtube.com/user/Barons44   ++HTKASC LINKS++ ++YOUTUBE: https://www.youtube.com/channel/UCKes11sC16NzpTC7Xcu9bLw  ++APPLE PODCASTS: http://bit.ly/HowToKillASacredCowPodcast  ++WEBSITE: www.howtokillasacredcow.com  ++INSTAGRAM: https://www.instagram.com/howtokillasacredcow/  ++FACEBOOK: http://bit.ly/HowToKillASacredCowFB  ++TWITTER: http://bit.ly/HowSacred  ++BITCHUTE: https://bit.ly/3fN8HLc  ++SPOTIFY: https://spoti.fi/3yyL8OA  ++ODYSEE: https://odysee.com/@HowToKillASacredCow:8   

Welcome to another episode of the Monday Night MasterDebaters, tonight we had Ryan from Dangerous World, Jay from How to Kill A Sacred Cow, Tyson our brother from Canada, and Jaymes from the band Nephrectomy. We had to talk about the Ottawa Freedom Convoy, the tyranny of Turd-eau, UN Troops on the ground, and Crushing of rights & civil liberties. True fascism, indoctrination in the Upside Down World and the dedication of the corporate media and counterparts to their narrative. We then switched gears to Ukraine, China Olympics, China potential Ebola spreader?, Fear of Death, Terrorism->Virus the use of invisible enemies, Transhumanism, Music and Music World in 2022, parenthood, and so much more. Enjoy the show, leave a review, and support the guests please & thank you! Jay from How to Kill a Sacred Cow Podcast IG: @jayhenehan @howtokillasacredcow howtokillasacredcow.com Jaymes from Nephrectomy IG: @elchapogonzo @nephrectomyofficial https://www.facebook.com/Nephrectomy https://nephrectomyslam.bandcamp.com Tyson our Canadian Brother IG: @that_crazy_canuk Ryan from Dangerous World Podcast Patreon: https://www.patreon.com/DangerousWorldPodcast/posts IG: @dangerousworldpod Merch: https://dangerousworldstore.com/ Mat from The Great Deception Podcast https://altmediaunited.com/the-great-deception-podcast/ IG: @thegreatdeceptionpodcast YouTube: https://youtube.com/user/Barons44 Bitchute: https://www.bitchute.com/channel/hPdLAyfQQ2DP/ Odysee: https://odysee.com/@TheGreatDeceptionPodcast:6 Email: thegreatdeceptionpodcast@gmail.com

In this episode, we talk about all things related to having a kidney removed, being born with one kidney, and how this impacts your kidney function.

Thank you for listening to another episode of DWP! Jaymes Grundmann of Nephrecotomy comes on yo y'all about his experiences and knowledge of fentanyl. We talk about all kinds of stuff and it felt like a great chat. Follow @elchapogonzo and @nephrectomyofficial on IG and check out nephrectomyslam.bandcamp.com Some of their music is played throughout the episode with Jaymes' permission! Nephrectomy is releasing an album this year titled “MEAT” Patreon.com/DangerousWorldPodcast for only $3 get the full versions of every episode plus bonus episodes For $5 get additional weekly bonus episodes! YOUTUBE CHANNEL LINK https://m.youtube.com/channel/UCZAc1An-9So-YI5WB53p6MQ IG: DangerousWorldPod EMAIL: DangerousWorldPodcast@gmail.com IG: DangerousWorldPod Male Grooming

Thank you for listening to another episode of DWP! Jaymes Grundmann of Nephrecotomy comes on yo y'all about his experiences and knowledge of fentanyl. We talk about all kinds of stuff and it felt like a great chat. Follow @elchapogonzo and @nephrectomyofficial on IG and check out nephrectomyslam.bandcamp.com Some of their music is played throughout the episode with Jaymes' permission! Nephrectomy is releasing an album this year titled “MEAT” Patreon.com/DangerousWorldPodcast for only $3 get the full versions of every episode plus bonus episodes For $5 get additional weekly bonus episodes! YOUTUBE CHANNEL LINK https://m.youtube.com/channel/UCZAc1An-9So-YI5WB53p6MQ IG: DangerousWorldPod EMAIL: DangerousWorldPodcast@gmail.com IG: DangerousWorldPod Male Grooming

Listen to a soundcast of the November 17, 2021 FDA approval of Keytruda (pembrolizumab) for the adjuvant treatment of patients with renal cell carcinoma at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions.

A panel of physicians including Dr. Brian Lane, Dr. Craig Rogers, Dr. Sam Bhayani, Dr. Alice Semerjian, Dr. Alon Weizer, and Dr. Jeremy Johnson discuss surgical techniques while reviewing partial nephrectomy videos.

Welcome to the Sterile Technique Podcast! It's the podcast about Surgical Technology. Whether you are a CST or CSFA, this podcast helps you earn CE credits and improve your surgery skills in the OR. This episode discusses the cover article of the September 2021 issue of The Surgical Technologist, which is the official journal of the Association of Surgical Technologists (AST). The article is titled, "Robot-Assisted Radical Nephrectomy with Inferior Vena Cava Thrombectomy". "Scrub in" at steriletpodcast.com and on Twitter, @SterileTPodcast (twitter.com/SterileTPodcast). This podcast is a Dybas Media production. Sound effects adapted from GarageBand and sindhu.tms at https://freesound.org/people/sindhu.tms/sounds/169065/ and licensed courtesy of https://creativecommons.org/licenses/by-nc/3.0/.

Joe Rogan has covid, Texas is doing The Purge, and we talk to our pals Jaymes and Tyler from metal band Nephrectomy about music, transgressive art, and how it fits into the left. ONE MILLION TRIGGER WARNINGS: If you don't like gross, offensive, over the top disgusting shit, listen to NPR this week instead ok??? Tracks played on the show are, in order: Nephrectomy - Meat Nephrectomy - Toxins. NEPHRECTOMY Jaymes Grundmann- Founder/Vocalist IG- @elchapogonzo Tyler Boyce - Guitarist, IG- @tyler_nephrectomy Band IG- @nephrectomyofficial Find all of our music at violentdefiant224.bandcamp.com We run a Kratom Shop in Denver called, Purple Greens, $100 kilos, call +1 (303) 238-5246 MERCH poddamnamerica.bigcartel.com PATREON Patreon.com/PodDamnAmerica NYC LIVE SHOW! GET TIX NOW! https://www.eventbrite.com/e/pod-damn-america-live-at-caveat-tickets-166560008469

Steven Campbell, MD, PhD, urologic surgeon, and member of the Section of Urologic Oncology in Cleveland Clinic's Glickman Urological and Kidney Institute, joins the Cancer Advances podcast to discuss the longstanding controversy between partial nephrectomy vs. radical nephrectomy. Listen as Dr. Campbell highlights the possible advantages and disadvantages of each approach and how to know which is best for your patient.

How are COVID-19 survivors fairing after hospital discharge? Find out about this and more in today's PV Roundup podcast.

We've all been in a doctor dentist some office where they hand you an authorization form and we sign, but do we ever read what we are signing? We should this case study shows what the consequences of someone calling in the wrong procedure. Consequences for the patient and her family and her credit score if she had let it. Christine was my second patient when I started my business I gave it my all. I charged her nothing, it was on a % of what I got back for her which was nothing. Was it a loss, no we both learned a very good lesson; the only one who really watches out for you is you- or your advocate. I wish I had met Christine before her procedure, things may have turned out differently. I will never forget Christine and I hope that you wouldn't either. Healthcare is ever changing and getting more and more complex every year. Navigating the Healthcare system can be challenging, to say the least. I will hold your hand every step of the way and guide you. You can't be expected to know what you don't know when it comes to questions to ask while in the doctor's office or while in the hospital. I am your eyes and ears and voice, always at your side.WWW.AtYourRequestPatientAdvocate.net or call 847-809-1214

Hello and Welcome to the Urology COViD Lecture Series Podcast! Brought to you by the UCSF Department of Urology. In today's episode, we have Dr. Gary Chien from Kaiser Permanente talking about Small Renal Mass: Step-by-step Retroperitoneal Robotic-Assisted Partial Nephrectomy (RAPN)​. Learn more by visiting our website! urologycovid.ucsf.edu.

This is a podcast article summary of "Long-Term Outcomes and Prognostic Factors in Kidney Transplant Recipients with Polycystic Kidney Disease" by Gauri Bhutani on behalf of coauthors.

Pr Pierre Bigot : Highlights des recommandations CCAFU 2020-2022 du cancer du reinQuelles sont les messages clés des nouvelles recommandations ? Quelles sont les nouveautés dans la prise en charge chirurgicale du cancer du rein métastatique ? Quelles sont les nouveautés dans le traitement médical de première ligne du cancer du rein métastatique ? Quels messages retenir pour les tumeurs kystiques et les angiomyolipomes sporadiques ?Le Pr Pierre Bigot (CHU d’Angers) répond à toutes vos questions !L’orateur n’a pas reçu de rémunération pour la réalisation de cet épisode.Cet épisode a été réalise grâce au soutien institutionnel des laboratoires IPSENPour aller plus loin :Recommandations françaises du Comité de Cancérologie de l’AFU : actualisation 2020-2022 : prise en charge du cancer du reinhttps://purol-12s.elsevierdigitaledition.com/2/https://www.urofrance.org/outils-et-recommandations/recommandations/recommandations-afu/classees-par-annee.htmlÉtude Carmena :Méjean A, Ravaud A, Thezenas S, Colas S, Beauval JB, Bensalah K, Geoffrois L, Thiery-Vuillemin A, Cormier L, Lang H, Guy L, Gravis G, Rolland F, Linassier C, Lechevallier E, Beisland C, Aitchison M, Oudard S, Patard JJ, Theodore C, Chevreau C, Laguerre B, Hubert J, Gross-Goupil M, Bernhard JC, Albiges L, Timsit MO, Lebret T, Escudier B. Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma. N Engl J Med. 2018 Aug 2;379(5):417-427. doi: 10.1056/NEJMoa1803675. Epub 2018 Jun 3. PMID: 29860937.Etude SURTIME :Bex A, Mulders P, Jewett M, Wagstaff J, van Thienen JV, Blank CU, van Velthoven R, Del Pilar Laguna M, Wood L, van Melick HHE, Aarts MJ, Lattouf JB, Powles T, de Jong Md PhD IJ, Rottey S, Tombal B, Marreaud S, Collette S, Collette L, Haanen J. Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical Trial. JAMA Oncol. 2019 Feb 1;5(2):164-170. doi: 10.1001/jamaoncol.2018.5543. Erratum in: JAMA Oncol. 2019 Feb 1;5(2):271. PMID: 30543350; PMCID: PMC6439568.Keynote 426 :Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D, Pouliot F, Alekseev B, Soulières D, Melichar B, Vynnychenko I, Kryzhanivska A, Bondarenko I, Azevedo SJ, Borchiellini D, Szczylik C, Markus M, McDermott RS, Bedke J, Tartas S, Chang YH, Tamada S, Shou Q, Perini RF, Chen M, Atkins MB, Powles T; KEYNOTE-426 Investigators. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med. 2019 Mar 21;380(12):1116-1127. doi: 10.1056/NEJMoa1816714. Epub 2019 Feb 16. PMID: 30779529. Checkmate 214 :Motzer RJ, Tannir NM, McDermott DF, Arén Frontera O, Melichar B, Choueiri TK, Plimack ER, Barthélémy P, Porta C, George S, Powles T, Donskov F, Neiman V, Kollmannsberger CK, Salman P, Gurney H, Hawkins R, Ravaud A, Grimm MO, Bracarda S, Barrios CH, Tomita Y, Castellano D, Rini BI, Chen AC, Mekan S, McHenry MB, Wind-Rotolo M, Doan J, Sharma P, Hammers HJ, Escudier B; CheckMate 214 Investigators. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. N Engl J Med. 2018 Apr 5;378(14):1277-1290. doi: 10.1056/NEJMoa1712126. Epub 2018 Mar 21. PMID: 29562145; PMCID: PMC5972549. Cet épisode a été réalisé grâce au soutien institutionnel des laboratoires IPSEN.Musique du générique : Via AudioNetworkResponsable projet

In this podcast Arjun Nathan discusses the paper: Predicting intraoperative and postoperative consequential events using machine learning techniques in patients undergoing robotic partial nephrectomy (RPN): Vattikuti Collective Quality Initiative (VCQI) database study (https://bjui-journals.onlinelibrary.wiley.com/doi/10.1111/BJU.15087) Arjun Nathan is an ST1 in Urology in North London, UK and NIHR Academic Clinical Fellow with the Royal College of Surgeons. He is also the BURST Treasurer and committee member.

In this episode, Elizabeth R. Plimack, MD, MS; Brian A. Costello, MD; and Martin H. Voss, MD, discuss current best practices for the first-line treatment of patients with metastatic renal cell carcinoma (RCC). Topics include:Choice of first-line therapyCombinations of targeted agents and immunotherapyCombinations of immune checkpoint inhibitorsActive surveillance and monitoringCytoreductive nephrectomyPresenters:Elizabeth R. Plimack, MD, MSChief, Division of Genitourinary Medical Oncology Director, Genitourinary Clinical Research Professor, Department of Hematology/Oncology Fox Chase Cancer Center Temple Health Philadelphia, PennsylvaniaBrian A. Costello, MDAssociate Professor of Oncology and UrologyDivision of Medical OncologyMayo ClinicRochester, MinnesotaMartin H. Voss, MDClinical Director, Genitourinary Medical Oncology ServiceMemorial Sloan Kettering Cancer CenterAssistant Professor Weill Cornell Medical CollegeNew York, New YorkContent based on an online CME program supported by educational grants from Eisai, Exelixis, Pfizer and EMD Serono, and Merck Sharp & Dohme Corp.Link to full program: https://bit.ly/32IS9gx

Quel traitement de première ligne proposer pour un cancer du rein métastatique ?Quelle classification pronostique utiliser ? Faut-il encore faire une néphrectomie de cytoréduction ?Quelles sont les dernières actualités dans le cancer du rein métastatique ?Le Pr Arnaud Mejean (Hôpital Européen Georges Pompidou) répond à toutes vos questions !L’orateur n’a pas reçu de rémunération pour la réalisation de cet épisode.Pour aller plus loin :- Lire ici : Méjean A, Ravaud A, Thezenas S, Colas S, Beauval J-B, Bensalah K, et al. Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma. N Engl J Med. 2 août 2018;379(5):417‑27.- Lire ici : Bex A, Mulders P, Jewett M, Wagstaff J, Thienen JV van, Blank CU, et al. Comparisonof Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical Trial. JAMA Oncol. 1 févr 2019;5(2):164‑70.- Lire ici : Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D, et al. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med. 21 mars 2019;380(12):1116‑27.- Lire ici : Motzer RJ, Penkov K, Haanen J, Rini B, Albiges L, Campbell MT, et al. Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med. 21 mars 2019;380(12):1103‑15.- Lire ici : otzer RJ, Tannir NM, McDermott DF, Arén Frontera O, Melichar B, Choueiri TK, et al. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. N Engl J Med. 5 avr 2018;378(14):1277‑90.- Lire ici : Recommandations françaises du comité de cancérologie de l’AFU – Actualisation 2020 : Prise en charge du cancer du rein métastatique.Réalisé avec le soutien institutionnel des laboratoires Ipsen.Musique du générique : Via AudioNetworkResponsable projet AFUF : Dr Benjamin PradèreProduction : La Toile Sur Ecoute See acast.com/privacy for privacy and opt-out information.

This episode of the "Ask Dr. Sundaram" video podcast from The Center for Men's and Women's Urology (1uro.com) in Gresham, Oregon, USA focuses on "A Robotic Nephrectomy (with illustrated terms)". Copyright 2019 all rights reserved.

This episode of the "Ask Dr. Sundaram" video podcast from The Center for Men's and Women's Urology (1uro.com) in Gresham, Oregon, USA focuses on "A Robotic Nephrectomy". Copyright 2019 all rights reserved.

Dr. Daniel George is Professor of Medicine and Surgery, Director of GU Oncology for the Duke Cancer Institute, and Co-Chair of the DCI Center for Prostate and Urologic Cancers. Dr George’s primary areas of interest are in drug development and optimizing care for patients with GU cancers, particularly prostate and kidney cancers. In this week's episode, Dr. George presents two contrasting cases with nephrectomy as a possible treatment path. Can you determine the best course of treatment for each patient? If you enjoyed this podcast, make sure to subscribe for more weekly education content from ASCO University. We truly value your feedback and suggestions, so please take a minute to leave a review. If you are an oncology professional and interested in contributing to the ASCO University Weekly Podcast, email ascou@asco.org for more information. TRANSCRIPT Welcome to the ASCO University Weekly Podcast. My name is Dr. Daniel George. And I'm a professor of medicine and surgery at Duke University. I'm also the director of GU oncology at the Duke Cancer Institute and co-chair of the DCI Center for Prostate and Neurologic Cancers. Today we'll discuss two similar cases of patients presenting with metastatic renal cell carcinoma in our multidisciplinary management options. Without any standard screening procedures, 20% to 30% of kidney cancer patients today present with metastatic disease. Historically, debulking nephrectomy has been our standard of care. And this has been based on old trials from the interferon era of treatments. Since then, many drugs have been approved for the management of patients with metastatic renal cell carcinoma, many of which have improved the progression free survival and overall survival of patients with metastatic disease, which may have had an impact on the landscape and role for debulking nephrectomy. Furthermore, metastatic kidney cancer patients can be risk stratified. There's a number of criteria used. But historically the most commonly used criteria has been the Memorial Sloan Kettering Cancer Center criteria. Which included five factors, including KPS score less than 70, a calcium score greater than 10, A serum hemoglobin of less than the lower limit of normal, and LDH greater than 1.5 times the upper limit of normal, or having their primary tumor in place, meaning no prior nephrectomy. If patients had zero of these factors they were considered good risk with the best survival. Patients with one or two of these factors are considered intermediate risk. And patients with three or more of these factors historically have been very poor risk, with median survivals of six months or less. The Carmena Study was a prospective, multi-center, randomized, non inferiority trial comparing upfront nephrectomy followed by sunitinib therapy, compared to upfront sunitinib therapy alone in patients with metastatic renal cell carcinoma amenable to cytoreductive nephrectomy. We'll get to these results in a moment. But the study population included, importantly, patients with e cog performance status zero or one. And 40% plus of these patients were considered poor risk, with the average sum of metastatic tumor burden being greater than five centimeters. So now, let's get to some modern cases. The first case we'll discuss is George. He's an 83-year-old man who presented with gross hematuria and a hemoglobin of 13.8 in the normal range. A CT scan revealed an eight centimeter right renal mass and multiple pulmonary mets, up to two centimeters in size. His e cog performance status is zero. And his calcium was 8.4, and LDH was normal as well. Our second case, for comparison, is Philip, a 76-year-old man who was found to have a 16 centimeter left renal mass incidentally on a spine MRI. This was confirmed by CT scan, along with some pulmonary nodules measuring up to 1.8 centimeters, as well as enlarged mediastinal lymph nodes up to two centimeters, and an eight millimeter liver lesion. His calcium score was 10.4. And his hemoglobin was 12.5, which was below the limit of normal. He had a normal LDH and an absolutely zero performance status. So for these two cases, we have four choices. The first choice is for both cases a nephrectomy followed by systemic treatment, our historical approach. The second is systemic therapy first, with plus or minus a subsequent nephrectomy for both cases. Our third choice would be to treat case number one with a nephrectomy, followed by systemic therapy, and case number two with systemic therapy first. And our fourth option would be systemic therapy first for case one and a nephrectomy first for case two. Now, to me, when I look at these cases, the correct answer is three. Nephrectomy first for case one, and systemic therapy first for case two. Let me explain. Even though these cases are fairly similar in age, gender, performance status, and had the presence of a large primary tumor, for case one this is an intermediate risk patient. This patient has lung only disease that's relatively low volume, a good performance status, and normal labs. In addition, he's symptomatic with gross hematuria. For these reasons, a debulking nephrectomy is really indicated. And because of his good performance status, he's very likely to recover well from the surgery, despite the fact that he's 83 years old. Case two is subtly different. This is actually a poor risk patient. Even though his e cog performance status is zero, he has an elevated calcium, a decreased hemoglobin, and he's got his primary tumor still in place. That puts him into a poor risk category. And some of these patients never recover from surgery well enough to get systemic therapy. He also has multi organ involvement, involving his lungs and nodes, and possibly even his liver. This is a patient that really mirrors the patient population of Carmena. Based upon this, I think systemic therapy first is a reasonable treatment option for this patient. If we actually look at the results of Carmena, the study confirmed that sunitinib therapy alone, systemic therapy, was non inferior, and actually trended towards improved survival compared to cytoreductive nephrectomy followed by sunitinib. The results suggest that for poor risk or for high volume metastatic patients, that systemic therapy first should be the standard of care. But, importantly, not included in a Carmena study were patients that had low volume metastatic disease and intermediate risk features, or good prognosis. These patients not included in the Carmena study might still benefit first from a debulking or cytoreductive nephrectomy. So thank you for listening to this week's episode of the ASCO University Weekly Podcast. For more information on the role of cytoreductive nephrectomy, including additional patient cases and opportunities for self-evaluation, visit the Comprehensive eLearning Center at university.asco.org. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care, and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.

Dr. Daniel Goldstein reviews the key data and limitations from the CARMENA trial that re-evaluated the role of nephrectomy in metastatic renal cell carcinoma (RCC), providing insight into how the data should be applied in clinical practice.

Welcome to the “Why Urology” podcast.  My name is Dr. Todd Brandt This podcast is my personal attempt to teach you about your genito-urinary tract, what can go wrong, and how your urologist may just become your superhero. The name of the podcast comes from my ongoing need to answer the question that I get so often from patients, friends, and family, “Why Urology? Why did you choose to become a urologist?” This episode comes to us thanks to a white mocha. Earlier in the day of this episode a patient of mine had woken up and decided to have a white chocolate mocha prior to coming to the hospital before his surgery. For those of you who have had surgery you know that there is a period of time when you can't eat or drink prior to having anesthesia. Because of his small indulgence we had a delay of two hours and a gap in the day. I took the opportunity to recruit our current robotic oncology fellow dr. Christopher Attalla for a discussion about the robotic partial nephrectomy.   For a physician, the end of medical school is the start of actual direct medical training. The first year is internship, then comes a residency of anywhere from 2 To 5 years depending on specialty and then after the residency training there may be a fellowship that can range from 1 to 4 years depending on the level of service subspecialty. Dr. Chris Atalla is doing a one year fellowship after his residency with the organization I work for, Minnesota Urology, focusing on robotic oncology surgery. He and I have been involved with quite a few cases together and he is doing an awesome job.  I recruited him to talk about one of the procedures he has seen quite a lot of halfway through his one year fellowship, the robotic partial nephrectomy.  Our conversation is in three parts. The first part is our discussion of the fellowship process and specializing in robotic surgery, where sometimes just familiarity with the tools of surgery requires time spent in the operating room  The second part is a discussion of the robotic partial nephrectomy specifically and the third last part we discuss the process of interviewing for residencies and begin to reminisce about being on the interview trail to get a coveted urology residency spot. Thank you for listening.  As always you can contact me at drbrandt@whyurologypodcast.com

Talking Urology Episode 8 Dr Hendrik Van Poppel. Nephrectomy

The British Association of Urological Surgeons nephrectomy audit for T1 renal tumours by BJUI - BJU International

05/27/2013 | Renal Cell Carcinoma Recurrence after Nephrectomy: CT Patterns and Protocol Optimization

Dr. Sumanta (Monty) Pal reviews the questions on the role of surgery and what type of surgery to pursue for early stage kidney cancer.

Dr. Sumanta (Monty) Pal reviews the questions on the role of surgery and what type of surgery to pursue for early stage kidney cancer.

Dr. Sumanta (Monty) Pal reviews the questions on the role of surgery and what type of surgery to pursue for early stage kidney cancer.

Dr. Sumanta (Monty) Pal of City of Hope Cancer Center in Duarte, CA describes optimal management of kidney cancer that is confined to the kidney, including surgery and the role of any additional post-surgical treatment. 

Dr. Sumanta (Monty) Pal of City of Hope Cancer Center in Duarte, CA describes optimal management of kidney cancer that is confined to the kidney, including surgery and the role of any additional post-surgical treatment. 

Dr. Sumanta (Monty) Pal of City of Hope Cancer Center in Duarte, CA describes optimal management of kidney cancer that is confined to the kidney, including surgery and the role of any additional post-surgical treatment. 

03/29/2010 | MDCT/CTA Following Nephrectomy for Renal Cell Carcinoma: Part 2

03/29/2010 | MDCT/CTA Following Nephrectomy for Renal Cell Carcinoma: Part 1

Host: Gary Kohn, MD Guest: Robert Thompson, MD Small renal tumors and surgical judgement. Amongst patients with small renal tumors, what is the benefit of a partial nephrectomy vs. a total, or radical nephrectomy? Dr. Robert Thompson, a urologic oncology fellow at Memorial Sloan Kettering Cancer Center, discusses research published in the Journal of Urology with your host, Dr. Gary Kohn.